Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Hematopoiesis News
Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
Subscribe|Follow Us On
Dee and Jimmy Haslam Make $10 Million Transformational Investment in Blood Cancer Research and Treatments at the Oxford-Harrington Rare Disease Centre
[Oxford Harrington Rare Disease Centre] The Oxford-Harrington Rare Disease Centre has received $10 million in transformational support from Dee and Jimmy Haslam to fuel research and drug development for chronic lymphocytic leukaemia and other rare blood cancers.
Transposable Elements Shape Stemness in Normal and Leukemic Hematopoiesis
[Nature Genetics] By identifying chromatin variants from accessibility measurements across leukemia stem cells, hematopoietic stem cells and downstream progeny, researchers identified transposable elements as genetic determinants of primitive versus mature populations
TCF3::HLF Orchestrates an Enhancer-Promoter Network with Activation of MEF2C to Promote Immature HSC Gene Expression in Leukemia
[Science Advances] Investigators used HiChIP mapping and genetic interference to analyze TCF3::HLF at the 3D genome level, revealing enhancer-promoter interactions that control gene activation or repression.
ATP2B1 Expression Identifies Human Hematopoietic Stem Cells with Superior Repopulation and Self-Renewal
[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified ATPase plasma membrane calcium transporting 1 (ATP2B1/PMCA1) as a cell surface marker that is heterogeneously expressed by CD49f+ long-term-HSC from fetal to adult hematopoiesis.
ENO1 Promotes Acute Myeloid Leukemia Progression through SCD1-Mediated Lipid Metabolism Reprogramming
[Blood Advances] Researchers investigated the association between high alpha-enolase (ENO1) expression, accelerated tumor progression, and poor AML prognosis.
DOCK1 Inhibitor Box5 (TFA) Suppresses Proliferation of AML Cell Lines and Prolongs Survival in AML Xenograft Models
[Scientific Reports] Scientists investigated the prognostic significance and functional roles of DOCK1 in AML. A novel small-molecule inhibitor targeting DOCK1 was identified and characterized.
High-Resolution Single-Cell Mapping of Clonal Hematopoiesis and Structural Variation in Aplastic Anemia
[Nature Genetics] Genomic profiling of 619 patients with aplastic anemia revealed clonal hematopoiesis in 69% of cases, with ASXL1, BCOR and BCORL1 identified as the most frequent CHIP mutations in pediatric cases.
CD84 Is a Specific Target for Acute Myeloid Leukemia CAR-T Cell Therapy
[Nature Communications] Investigators identified CD84 as a promising target for AML immunotherapy, displaying a unique expression profile: it is robustly and stably expressed by blasts, particularly in relapsed disease, and negligible on normal hematopoietic stem/progenitor cells.
ATRA Improves Megakaryopoiesis in Immune Thrombocytopenia through Up-Regulating the HIF-1α/SPHK2/S1P Pathway
[Science Advances] The authors observed disorganized cytoskeleton and impaired proplatelet formation in megakaryocytes from patients with immune thrombocytopenia.
Immune Regulation by Erythroid Cells: How Erythroid Progenitor Cells and Mature Red Blood Cells Shape Immunity
[Nature Reviews Immunology] Scientists highlight the emerging field of erythroid–immune crosstalk and its translational potential in the settings of infection, cancer, pregnancy, and chronic inflammatory conditions.
MDM2 Inhibitors in Myeloid Cancers: From Basic Biology to Clinical Use in Myeloproliferative Neoplasms
[Leukemia] The authors integrate mechanistic foundations, clinical development, resistance biology, and future directions, highlighting how decades of basic science have reshaped p53 reactivation into a precision therapeutic paradigm in myeloid disease.
Orca Bio Announces US FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies
[Orca Bio] Orca Bio announced that the US FDA has granted RMAT designation to Orca-Q, Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy for the treatment of high-risk hematologic malignancies.
Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.
